Centessa Pharmaceuticals (NASDAQ:CNTA) Coverage Initiated at Piper Sandler

Stock analysts at Piper Sandler initiated coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA) in a research note issued on Monday, MarketBeat reports. The brokerage set an “overweight” rating and a $38.00 price target on the stock. Piper Sandler’s target price would indicate a potential upside of 187.23% from the stock’s current price.

Several other equities research analysts also recently commented on the stock. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating for the company. Morgan Stanley reaffirmed an “overweight” rating and set a $27.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Finally, Guggenheim reissued a “buy” rating and issued a $28.00 price objective on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Centessa Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $27.71.

Centessa Pharmaceuticals Trading Down 8.0 %

Centessa Pharmaceuticals stock opened at $13.23 on Monday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The stock has a market cap of $1.74 billion, a PE ratio of -8.65 and a beta of 1.54. The stock has a 50-day moving average of $16.40 and a two-hundred day moving average of $16.41. Centessa Pharmaceuticals has a one year low of $7.75 and a one year high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.04. On average, research analysts anticipate that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

Insider Activity

In other news, insider David M. Chao sold 7,000 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $17.17, for a total transaction of $120,190.00. Following the sale, the insider now owns 225,007 shares of the company’s stock, valued at $3,863,370.19. This trade represents a 3.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Saurabh Saha sold 55,000 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $15.77, for a total transaction of $867,350.00. Following the completion of the transaction, the chief executive officer now owns 429,398 shares of the company’s stock, valued at approximately $6,771,606.46. This represents a 11.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 260,168 shares of company stock valued at $4,309,568 in the last quarter. 11.59% of the stock is currently owned by company insiders.

Institutional Trading of Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. purchased a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth about $31,000. GAMMA Investing LLC raised its holdings in Centessa Pharmaceuticals by 29.1% in the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock worth $64,000 after purchasing an additional 865 shares during the period. Barclays PLC boosted its position in Centessa Pharmaceuticals by 1,414.9% during the fourth quarter. Barclays PLC now owns 5,302 shares of the company’s stock worth $89,000 after purchasing an additional 4,952 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in Centessa Pharmaceuticals in the fourth quarter valued at approximately $162,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $171,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.